SCHEMBL3674585

SCHEMBL3674585

NCc1ccccc1COC(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.61
TDP1 Q9NUW8 3/20 0.59
KMT2A Q03164 3/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
KDM4E B2RXH2 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 4/20 0.50
MAPK1 P28482 2/20 0.50
HIF1A Q16665 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
ALDH1A1 P00352 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.46
F2 P00734 1/20 0.45
MAPT P10636 3/20 0.44
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5085480 0.91 PPARG (0.71) PPARGTDP1KMT2ASLC6A2SLC6A3
Ethyl Benzoate SCHEMBL29016078 0.84 SMN1; SMN2 (0.56) TDP1KMT2ASLC6A2SLC6A3SMN1; SMN2
SCHEMBL6243415 0.84 PPARG (0.63) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL28982407 0.82 PPARG (0.61) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL6245188 0.82 PPARG (0.61) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL4445832 0.82 PPARG (0.61) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL27841681 0.81 PPARG (0.60) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL4577944 0.81 PPARG (0.65) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL336833 0.80 PPARG (0.63) PPARGTDP1KMT2ASLC6A2SLC6A3
SCHEMBL4070163 0.79 LMNA (0.70) PPARGTDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105287472-B Antibacterial agent is used to treat the purposes of epithelial-related disease condition 西格纳姆生物科学公司 2019-04-12 CN disclosed
CN-105287472-A Antibacterial agent for treating the related state of illness about epithelium SIGNUM BIOSCIENCES INC 2016-02-03 CN disclosed
CN-102655745-B Use of antibacterial agents for treating epithelial-related conditions SIGNUM BIOSCIENCES, INC. (US) 2016-01-06 CN disclosed
CN-102203067-B Hedgehog pathway modulators IRM LLC 2014-01-15 CN disclosed
US-20130190502-A1 ACYLATION REACTION OF HYDROXYL GROUP TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-07-25 US disclosed
US-8431709-B2 Acylation reaction of hydroxyl group TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-04-30 US disclosed
US-20100249422-A1 ACYLATION REACTION OF HYDROXYL GROUP TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190502-A1 ACYLATION REACTION OF HYDROXYL GROUP ADH5, ADH1A, ACADM PPARG 350/4885TDP1 4433/4885KMT2A 581/4885
US-20100249422-A1 ACYLATION REACTION OF HYDROXYL GROUP ADH5, ADH1A, ACADM PPARG 350/4885TDP1 4433/4885KMT2A 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.